Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Investigators at George Washington University release new data on angiogenesis
May 19th, 2009
According to recent research published in the journal Best Practice & Research Clinical Haematology, "Recent advances in the understanding of the pathogenesis of cancer have led to the introduction of a variety of biological agents with novel mechanisms of action into clinical trials and even into clinical practice. In Particular, tumour-associated neoangiogenesis has become a major target for this new class of antineoplastic agents." "Five anti-angiogenic agents (thalidomide, lenalidomide, bevacizumab, sunitinib, sorafenib) have already obtained US Food and Drug Administration approval for clinical use, and many others have entered clinical trials. Many new...
Source: Cancer Weekly (2009-05-19)
|
